Head-to-head Comparison of Diagnosis Value of Pulmonary Fibrosis on 68Ga-FAPI-04 and 18F-FDG PET-CT
Sponsored by Peking Union Medical College Hospital
About this trial
Last updated 4 years ago
Study ID
PUMCH-NM-FAPI-PF
Status
Not yet recruiting
Type
Interventional
Phase
Phase 1
Placebo
No
Accepting
18 to 80 Years
All
Not accepting
Healthy Volunteers
Trial Timing
Ended 2 years ago
What is this trial about?
68Ga-fibroblast activating protein inhibitors(FAPI) has been developed as a tumor-targeting
agent as fibroblast activation protein is overexpressed in cancer-associated fibroblasts and
some inflammation,such as inflammatory bowel disease. And it might be more sensitive than FDG
in detecting a certain type of inflammations according to our preliminary research. Thus this
prospective study is going to investigate whether 68Ga-FAPI PET/CT may be superior for
diagnosis, therapy response assessment and follow-up of Pulmonary fibrosis than 18F-FDG
PET/CT.
What are the participation requirements?
Inclusion Criteria
- suspected or confirmed pulmonary fibrosis patients;
- signed written consent.
Exclusion Criteria
- pregnancy;
- breastfeeding;
- known allergy against FAPI
- any medical condition that in the opinion of the investigator may significantly interfere with study compliance